As a functional, practical and intelligent way to regulate medical products in today’s globalized world - especially with increasing public health needs, limited resources and demand for faster and better treatments - the use of regulatory decisions from other jurisdictions represents a powerful and effective alternative.
Latin America is moving towards the increasing use of these regulatory pathways of reliance. Undoubtedly, Brazil is the pioneer in this field, but Argentina, Peru, Mexico and Panama have also started to integrate these practices and have recorded positive experiences in areas such as international certification of good manufacturing practices and collaboration with regulators abroad.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze